Todd Krause is a partner at Desmarais LLP with more than 20 years of experience litigating patents for some of the world’s largest pharmaceutical and biotechnology companies. Dr. Krause has litigated a broad range of patent issues in the life sciences industry, including many cases brought under the Hatch-Waxman Act against generic drug companies, biologic drugs, gene amplification techniques, cell-based assays, veterinary vaccines, and recombinant nucleic acids and proteins.
Dr. Krause has served as trial and litigation counsel for a variety of blockbuster drugs and biologics (whose annual sales exceeded $1 billion). Most recently, he served as trial counsel for Johnson & Johnson subsidiary Janssen Pharmaceuticals in two Hatch-Waxman trials related to the blockbuster prostate cancer drug Zytiga® and the blockbuster blood-thinner Xarelto®. Dr. Krause also recently served as trial and/or litigation counsel for Merck on the blockbuster cancer immunotherapy Keytruda®; Johnson & Johnson subsidiary Janssen Pharmaceuticals on the pain treatment Nucynta®; Forest Laboratories on the blood pressure reducing agent Bystolic®; Sunovion Pharmaceuticals on the asthma and chronic obstructive pulmonary disease treatment Xopenex HFA®; and Merck and Schering on the blockbuster cholesterol lowering drugs Zetia® and Vytorin®.
Prior to joining Desmarais LLP as a partner in 2018, Dr. Krause was a partner in Sidley Austin LLP’s New York office where he worked for more than a decade in the firm’s Intellectual Property Litigation Practice.
Professional Memberships
American Bar Association, New York Intellectual Property Law Association, American Intellectual Property Law Association, New Jersey Intellectual Property Law Association, American Association of the Advancement of Science
Personal
- University of Houston Law Center, J.D., cum laude, 1997
- University of Texas at Austin, Ph.D., Biological Sciences
(Neuroscience), 1993; Honor Society of Phi Kappa Phi;
Doctoral Dissertation Award
- Trinity University, B.A. economics, 1985
Last updated 13th May 2019
